It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

G7 to donate 1 billion COVID-19 vaccine doses to poorer countries

British Prime Minister Boris Johnson expects the Group of Seven to agree to donate 1 billion COVID-19 vaccine doses to poorer countries.

Article originally published by Reuters. Hargreaves Lansdown is not responsible for its content or accuracy and may not share the author's views. News and research are not personal recommendations to deal. All investments can fall in value so you could get back less than you invest.

  • Britain to give 100 million doses.
  • Biden pledges 500 million doses.
  • Campaigners: 1 billion doses is not enough.

British Prime Minister Boris Johnson expects the Group of Seven to agree to donate 1 billion COVID-19 vaccine doses to poorer countries during its summit starting on Friday, and help inoculate the world by the end of next year.

Just hours after U.S. President Joe Biden vowed to supercharge the battle against the coronavirus with a donation of 500 million Pfizer shots, Johnson said Britain would give at least 100 million surplus vaccines to the poorest nations.

Johnson has already called on G7 leaders to commit to vaccinate the entire world by the end of 2022 and the group is expected to pledge 1 billion doses during its three-day summit in the English seaside resort of Carbis Bay.

Some campaign groups condemned the plan as a drop in the ocean, with Oxfam estimating that nearly 4 billion people will depend for vaccines on COVAX, the programme that distributes COVID-19 shots to low and middle income countries.

"As a result of the success of the UK's vaccine programme we are now in a position to share some of our surplus doses with those who need them," Johnson will say on Friday, according to excerpts of the announcement released by his office.

"In doing so we will take a massive step towards beating this pandemic for good."

COVID-19 has killed around 3.9 million people and ripped through the global economy, with infections reported in more than 210 countries and territories since the first cases were identified in China in December 2019.

GLOBAL EFFORT

While scientists have brought vaccines to market at breakneck speeds - Britain has given a first dose to 77% of its adult population and the United States 64% - they say the pandemic will only end once all countries have been vaccinated.

With a global population nearing 8 billion and most people needing two doses, if not booster shots to tackle variants as well, campaigners said the commitments marked a start but that world leaders needed to go much further, and much faster.

"If the best G7 leaders can manage is to donate 1 billion vaccine doses then this summit will have been a failure," Oxfam's health policy manager Anna Marriott said, adding that the world would need 11 billion doses to end the pandemic.

Oxfam also called on G7 leaders to support a waiver on the intellectual property behind the vaccines.

"The lives of millions of people in developing countries should never be dependent on the goodwill of rich nations and profit-hungry pharmaceutical corporations," Marriott said.

Of the 100 million British shots, 80 million will go to the COVAX programme led by the World Health Organization (WHO) and the rest will be shared bilaterally with countries in need.

Johnson echoed Biden in calling on his fellow leaders to make similar pledges and for pharmaceutical companies to adopt the Oxford-AstraZeneca model of providing vaccines at cost for the duration of the pandemic.

Leaving poorer countries to deal with the pandemic alone risks allowing the virus to further mutate and evade vaccines. Charities have also said that logistical support will be needed to help administer large numbers of vaccines in poorer countries.

The British doses will be drawn from the stock it has already procured for its domestic programme, and will come from suppliers Oxford-AstraZeneca, Pfizer-BioNTech, Janssen, Moderna and others.

(Reporting by Kate Holton; Editing by Guy Faulconbridge, Grant McCool and Alex Richardson)


Copyright (2021) Thomson Reuters. This article was written by Kate Holton from Reuters and was legally licensed through the Industry Dive publisher network. Please direct all licensing questions to legal@industrydive.com.


Newsroom: our daily email

Sign up to receive the daily headlines that matter to investors.


Please correct the following errors before you continue:

    Existing client? Please log in to your account to automatically fill in the details below.

    Loading

    Your postcode ends:

    Not your postcode? Enter your full address.

    Loading

    Hargreaves Lansdown PLC group companies will usually send you further information by post and/or email about our products and services. If you would prefer not to receive this, please do let us know. We will not sell or trade your personal data.

    Article originally published by Reuters. Hargreaves Lansdown is not responsible for its content or accuracy and may not share the author's views. News and research are not personal recommendations to deal. All investments can fall in value so you could get back less than you invest.

    Free news email alerts

    • Daily and weekly news
    • Major Publishers
    Register